FEATURED IN CNN + KFF HEALTH NEWS
Breast Cancer Financial Toxicity: My Story in CNN and KFF Health News
A national investigation examined what patients endure when cancer-drug dosages, side effects, costs, and financial incentives collide. My part of the story was what happened when the medication I could tolerate became financially impossible to obtain.
Co-published by CNN and KFF Health News · Reporting by Arthur Allen · August 19, 2026
How much of a cancer drug is enough? The reporting examines a question with no good answer: whether lower doses or shorter courses of some cancer drugs might preserve effectiveness while sparing patients the worst of the toxicity, and the cost. Almost no one in American healthcare has a financial reason to find out. Drugmakers price by the dose. Hospitals are paid by the infusion. The studies that would tell patients what they actually need are the studies nobody profits from running.
I was not in this story as a dosing expert, and I will not pretend to be one. I was in it as what that uncertainty looks like when it lands on one woman: the side effects, the coverage fight, and the price tag that followed me across the country. The full investigation is also available free from KFF Health News.
What happened to me
Verzenio made me so sick, so exhausted, and so disoriented that I considered suicide. I say that plainly because tolerability is not a footnote in cancer care. It decides whether a woman can stay on the medication that is supposed to keep her alive. If you are struggling, call or text 988, the Suicide & Crisis Lifeline.
I switched to Kisqali, and it was tolerable. Then, in September 2025, my coverage for Kisqali stopped while I was paying a $6,000 monthly insurance premium. The cash price was at least $16,000 a month.
I fought the insurer for three months. Then Joe and I sold our house and our belongings in Palm Desert, California, and moved to Durham, North Carolina, where we found an insurance plan that would cover my medication. We did not relocate for a job or a fresh start. We relocated for a formulary.
“I was left to research these medications on Facebook and Reddit. The only people talking about the daily reality of these drugs were other patients. But I wanted the studies. I wanted practical guidance.”
— Allegra Warfield, quoted by CNN and KFF Health News
What financial toxicity actually looks like
Financial toxicity is the clinical term for what happens when the cost of staying alive becomes its own disease. It is not one large bill. It is choosing between household necessities and an insurance premium. It is months of denials and appeals conducted from waiting rooms and infusion chairs, an unpaid full-time job assigned to you on the day of diagnosis. It is selling a home and moving 2,300 miles because that was the only route left to the medication that worked.
“Eventually the choice was this: sell everything for a chance at life, or go bankrupt trying to survive a system that protects profit better than it protects us.”
I wrote that the week we left Palm Desert, and I stand by every word. A home, a zip code, a life we built, traded for a formulary. That is what financial toxicity looks like: not a bill, a relocation.
Why I do this work
I am a breast cancer advocate, writer, and speaker. I am an I-SPY 2.2 clinical trial alumna, a National Breast Cancer Coalition Project LEAD graduate, and a member of the Quantum Leap Healthcare Collaborative Patient Advisory Committee, and I am a contributing writer for CURE Magazine and Bezzy.
What I bring is lived experience, patient advocacy, systems analysis, and research literacy. What I do not offer is individualized medical advice. I read the studies because I needed them and nobody handed them to me. Now I translate that work for the women still doing math with mortality in the dark, in my writing and from stages.
Patients deserve evidence, access, and a life they can still afford to live.
I write and speak about financial toxicity, survivorship, hereditary risk, patient advocacy, and the hidden labor of getting good care. Follow the work, and bring it to the rooms that need it.